NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NEOGAP Therapeutics AB

NEOGAP Therapeutics AB

Private
StockholmHealthcare & Life Scienceshttps://neogap.se/

Last Round

Early Funding

Feb 11, 2026

Est. Valuation

$23M

Total Funding Raised

$13.1M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

NEOGAP Therapeutics AB is a biotechnology company that develops personalized cancer immunotherapy designed to precisely target and eliminate cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

personalized cancer immunotherapyneoantigen predictionT-cell therapypersonalized medicinePIORMATTcancer vaccinebioinformaticsclinical-stage biotechcell therapytumor-reactive T-cellsdrug discoveryimmunotherapybiotech startupprecision oncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NEOGAP Therapeutics AB Comps

Public and private peers based on sector, stage, and business model.

NEOGAP Therapeutics AB comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

NEOGAP Therapeutics AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingFeb 11, 2026
GrantNov 5, 2025
GrantFeb 26, 2025
GrantMar 26, 2024
GrantNov 9, 2023
VC Round
Nov 9, 2023

Key People

Founding team and executive leadership

Samuel Svensson

CEO

Executive Team

Guro Gafvelin

Chief Technology Officer

Executive Team

Andrea Salmén

Chief Operating Officer

Executive Team

NEOGAP Therapeutics AB Investors

Notable investors and investment history

NEOGAP Therapeutics AB investors
InvestorRounds
European Innovation Council FundGrant
Eurostars SME programmeGrant
VinnovaGrant
ScietyVC Round, Early Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 11, 2026

    Raised $9.8M in early funding.

  • Feb 11, 2026

    Partnered with NorthX Biologics to advance cell therapy manufacturing.

NEOGAP Therapeutics AB Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NEOGAP Therapeutics AB Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NEOGAP Therapeutics AB's valuation, stock price, and market status.

Firmographic Details

HeadquartersStockholm
Employee Range25
Year Founded2016
Last FundingFeb 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.